Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune discovered aducanumab, a human monoclonal antibody targeting amyloid beta for the treatment of Alzheimer's disease, and licensed it to Biogen.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business